EGFR and non-small cell lung carcinoma: Over the last decade, the discovery of epidermal growth factor receptor (EGFR) gene mutations and the development of tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment strategies for patients with advanced non-small cell lung cancer (NSCLC) (1–5).